Intellia Therapeutics (NTLA) Receivables - Net (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Receivables - Net for 12 consecutive years, with $9.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Net fell 13.07% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $9.1 million (down 13.07% YoY), while the FY2025 annual figure was $9.5 million, up 11.54% from the prior year.
• Receivables - Net slipped to $9.1 million in Q1 2026 per NTLA's latest filing, from $9.5 million in the prior quarter.
• Across five years, Receivables - Net topped out at $36.5 million in Q4 2023 and bottomed at $1.8 million in Q1 2022.
• Historically, Receivables - Net has averaged $10.8 million across 5 years, with a median of $8.9 million in 2024.
• Annual changes were most pronounced in 2023 — Receivables - Net jumped 867.52% — and 2024, when it sank 76.64%.
• Intellia Therapeutics' Receivables - Net stood at $3.8 million in 2022, then surged by 867.52% to $36.5 million in 2023, then tumbled by 76.64% to $8.5 million in 2024, then gained by 11.54% to $9.5 million in 2025, then retreated by 3.88% to $9.1 million in 2026.
• Business Quant data shows NTLA's Receivables - Net at $9.1 million in Q1 2026, $9.5 million in Q4 2025, and $11.0 million in Q3 2025.